Effects of Blueberry-polyphenols on Endothelial Function, Absorption and Metabolism

November 2, 2015 updated by: Klinik für Kardiologie, Pneumologie und Angiologie, Heinrich-Heine University, Duesseldorf

Sustained Effects of Blueberry Polyphenols on Vascular Function in Healthy Individuals

Diets rich in fruits and vegetables have been linked to favorable cardiovascular outcomes in epidemiological studies.

Dietary intervention studies with certain micronutrients have shown promising effects on surrogate parameters of vascular risk including blood pressure, endothelial function and cholesterol levels. Wild blueberries have gained attention due to their high content of phytochemicals and particularly anthocyanins. Whether wild blueberries can improve vascular function and health when given over relevant time periods and in relevant populations is not known. Therefore, it is the overall hypothesis of the study proposal that chronic consumption of wild blueberries can improve endothelial function, a prognostically validated surrogate of cardiovascular risk.

Study Overview

Status

Completed

Conditions

Study Type

Interventional

Enrollment (Actual)

45

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Duesseldorf, Germany, 40225
        • Division of Cardiology, Pulmonary Disease and Vascular Medicine, University Hospital Duesseldorf

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • healthy male subjects without clinical signs or symptoms of cardiovascular disease
  • 18-70 years

Exclusion Criteria:

  • cardiovascular disease
  • acute inflammation
  • cardiac arrhythmia
  • renal failure
  • heart failure (NYHA II-IV)
  • diabetes mellitus
  • C- reactive protein > 1mg/dl
  • malignant disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Blueberry Group
Dietary Supplement: 22 gram freeze-dried blueberry powder per day
22 grams freeze-dried blueberry powder per day. Sustained intake (2x 11 grams daily over 1 month) of a drink consisting on freeze-dried wild blueberry powder dissolved in water
Placebo Comparator: Placebo Group
blueberry polyphenol deprived powder 22 gram per day
Sustained intake (2x 11 grams daily over 1 month) of a drink consisting in placebo powder dissolved in water

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Endothelial function
Time Frame: baseline and 1 month
Determination of endothelial function by Flow mediated dilation (FMD) 0 and 2 hours postconsumption
baseline and 1 month

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pulse wave velocity
Time Frame: baseline and 1 month
Measured by SphygmoCor 0 and 2 hours postconsumption
baseline and 1 month
Blood pressure
Time Frame: baseline and 1 month
automatical measurements, 0 and 2 hours postconsumption
baseline and 1 month
Blood lipids
Time Frame: baseline and 1 month
biochemical analysis, 0 and 2 hours postconsumption
baseline and 1 month

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Plasma blueberry polyphenol metabolites
Time Frame: baseline and 1 month
measured by liquid chromotography- mass spectrometry (LC/MS) 0 and 2 hours postconsumption
baseline and 1 month
Peripheral blood mononuclear cell-derived gene expression analysis
Time Frame: baseline and 1 month
exploratory measures; measured by Agilent Human GZ 4x44 v2 Microarray
baseline and 1 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Ana Rodriguez-Mateos, PhD, Division of Cardiology, Pulmonology and Vascular Medicine, University Hospital Duesseldorf
  • Study Chair: Christian Heiss, MD, Division of Cardiology, Pulmonology and Vascular Medicine, University Hospital Duesseldorf

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2014

Primary Completion (Actual)

September 1, 2015

Study Completion (Actual)

September 1, 2015

Study Registration Dates

First Submitted

July 8, 2015

First Submitted That Met QC Criteria

August 7, 2015

First Posted (Estimate)

August 13, 2015

Study Record Updates

Last Update Posted (Estimate)

November 3, 2015

Last Update Submitted That Met QC Criteria

November 2, 2015

Last Verified

November 1, 2015

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on Blueberry Group

3
Subscribe